MyFinsight
Home
About
Contact
uthr: the income statement
Download
Download image
Product And Service
Other
$6,900K
Adcirca
$9,700K
Unituxin
$47,900K
Orenitram
$131,100K
Remodulin
$125,900K
Nebulized Tyvaso
$141,800K
Tyvaso DPI
$336,200K
Other income, net
$6,100K
(5.17%↑ Y/Y)
Interest income
$46,400K
(-6.83%↓ Y/Y)
Total revenues
$799,500K
(6.76%↑ Y/Y)
Total other income,
net
$49,500K
(8.79%↑ Y/Y)
Operating income
$388,500K
(13.23%↑ Y/Y)
Interest expense
$3,000K
(-70.30%↓ Y/Y)
Total operating
expenses
$411,000K
(1.28%↑ Y/Y)
Income before income
taxes
$438,000K
(12.71%↑ Y/Y)
Selling, general, and
administrative
$182,600K
(-16.70%↓ Y/Y)
Research and development
$127,500K
(23.19%↑ Y/Y)
Cost of sales
$100,900K
(21.42%↑ Y/Y)
Net income
$338,700K
(9.58%↑ Y/Y)
Income tax expense
$99,300K
(24.91%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)